We are thrilled to welcome Andreas Strüngmann to this year’s conference. He began his career after studying medicine in 1986. Together with his twin brother Thomas, he founded the pharmaceutical company Hexal. The siblings’ company has grown to be one of Germany’s largest generic drug manufacturers, with over one billion euros in revenue. In 2005, they sold the company to Novartis. Since then, he has invested in young, rising companies and is a generous donor for science and research. Among others, Mr. Strüngmann was one of the first investors of BioNTech SE and, therefore, had a significant influence on the development of the Covid-19 vaccine. Due to Strüngmann’s accomplishments, he was awarded the Person of the Year 2020 by Handelsblatt. We are honored to have Andreas Strüngmann join us as a speaker and look forward to listening to his thoughts on long term innovation investments.